Apogee starts Phase 2 AD trial for APG777; Phase 1 shows ~75-day half-life

Apogee Therapeutics, Inc.

Initiated dosing in Phase 2 trial of APG777 for moderate-to-severe atopic dermatitis (AD).
Phase 1 healthy volunteer data showed half-life of ~75 days and potentially best-in-class PK profile.
16-week proof-of-concept data from Part A expected in 2H 2025; dose optimization Part B also planned.
APG777 designed for less frequent dosing: 6 injections during induction vs 11 for lebrikizumab, 70-90% fewer in maintenance.
Phase 2 asthma trial expected to initiate in 2025; pipeline-in-a-product strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.